7SVT

Mycobacterium tuberculosis 3-hydroxyl-ACP dehydratase HadAB in complex with 1,3-diarylpyrazolyl-acylsulfonamide inhibitor

7SVT の概要

• エントリーDOI: 10.2210/pdb7svt/pdb
• 分子名称: HadA, (3R)-hydroxyacyl-ACP dehydratase subunit HadB, 3-[1-(4-bromophenyl)-3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(methanesulfonyl)propanamide, ... (7 entities in total)
• 機能のキーワード: mycobacterium tuberculosis, tuberculosis drug discovery, 3-hydroxyl-acp dehydratase, hadab/bc, structural genomics, tb structural genomics consortium, tbsgc, lipid binding protein, lyase-inhibitor complex, lyase/inhibitor
• 由来する生物種: Mycobacterium tuberculosis; 詳細
• タンパク質・核酸の鎖数: 8
• 化学式量合計: 132149.35

構造登録者

Krieger, I.V.,Sacchettini, J.C.,TB Structural Genomics Consortium (TBSGC) (登録日: 2021-11-19, 公開日: 2022-11-16, 最終更新日: 2023-10-18)

主引用文献

Singh, V.,Grzegorzewicz, A.E.,Fienberg, S.,Muller, R.,Khonde, L.P.,Sanz, O.,Alfonso, S.,Urones, B.,Drewes, G.,Bantscheff, M.,Ghidelli-Disse, S.,Ioerger, T.R.,Angala, B.,Liu, J.,Lee, R.E.,Sacchettini, J.C.,Krieger, I.V.,Jackson, M.,Chibale, K.,Ghorpade, S.R.
1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex in Mycobacterium tuberculosis .
Acs Infect Dis., 8:2315-2326, 2022

PubMed Abstract: Alternative mode-of-inhibition of clinically validated targets is an effective strategy for circumventing existing clinical drug resistance. Herein, we report 1,3-diarylpyrazolyl-acylsulfonamides as potent inhibitors of HadAB/BC, a 3-hydroxyl-ACP dehydratase complex required to iteratively elongate the meromycolate chain of mycolic acids in (). Mutations in compound -resistant mutants mapped to HadC (Rv0637; K157R), while chemoproteomics confirmed the compound's binding to HadA (Rv0635), HadB (Rv0636), and HadC. The compounds effectively inhibited the HadAB and HadBC enzyme activities and affected mycolic acid biosynthesis in , in a concentration-dependent manner. Unlike known 3-hydroxyl-ACP dehydratase complex inhibitors of clinical significance, isoxyl and thioacetazone, 1,3-diarylpyrazolyl-acylsulfonamides did not require activation by EthA and thus are not liable to EthA-mediated resistance. Further, the crystal structure of a key compound in a complex with HadAB revealed unique binding interactions within the active site of HadAB, providing a useful tool for further structure-based optimization of the series.

PubMed: 36325756
DOI: 10.1021/acsinfecdis.2c00392

実験手法

X-RAY DIFFRACTION (2.4 Å)